Allergy Therapeutics (AGY) — Capital Reinvestment Ratio
Latest as of December 2021:
0.31x
Allergy Therapeutics (AGY) has a Capital Reinvestment Ratio of 0.31x as of December 2021, meaning it reinvests 0% of its operating cash flow (GBX3.71 Million) in capital expenditures (GBX1.15 Million). See Allergy Therapeutics (AGY) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.31x
Capex / Operating Cash Flow
Operating Cash Flow
GBX3.71 Million
GBX
Capital Expenditures
GBX1.15 Million
GBX
Data as of
Dec 2021
Most recent filing
Allergy Therapeutics Capital Reinvestment Ratio (2003–2021)
This chart tracks Allergy Therapeutics's Capital Reinvestment Ratio across 11 annual periods.
Annual Capital Reinvestment Ratio for Allergy Therapeutics (2003–2021)
Year-by-year Capital Reinvestment Ratio for Allergy Therapeutics from 2003 to 2021. For live market cap and broader valuation context, see Allergy Therapeutics market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (GBX) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.30x | GBX8.52 Million | GBX2.56 Million | ▲ +45.0% |
| 2020 | 0.21x | GBX12.28 Million | GBX2.55 Million | ▼ -58.7% |
| 2019 | 0.50x | GBX5.60 Million | GBX2.81 Million | ▼ -94.0% |
| 2017 | 8.43x | GBX178.00K | GBX1.50 Million | ▲ +2312.2% |
| 2015 | 0.35x | GBX3.12 Million | GBX1.09 Million | ▼ -15.5% |
| 2014 | 0.41x | GBX2.17 Million | GBX898.00K | ▲ +22.4% |
| 2013 | 0.34x | GBX2.43 Million | GBX821.00K | ▼ -22.9% |
| 2012 | 0.44x | GBX2.88 Million | GBX1.26 Million | ▼ -56.1% |
| 2010 | 1.00x | GBX1.70 Million | GBX1.70 Million | ▲ +150.2% |
| 2004 | 0.40x | GBX1.91 Million | GBX760.00K | ▲ +105.8% |
| 2003 | 0.19x | GBX2.10 Million | GBX406.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow